The Lophora team has published a paper detailing the discovery and structure of the lead clinical candidate LPH-5 in the Journal of Medicinal Chemistry.
The Lophora team is pleased to announce the publication detailing the discovery and structure of our lead clinical candidate LPH-5 in this month’s Journal of Medicinal Chemistry. LPH-5 is a novel, patent-protected, next-generation psychedelic with the potential to treat neurological and psychiatric disorders, such as treatment-resistant depression, PTSD, alcohol use disorder and addiction.
As LPH-5 approaches First-in-Human trials, we celebrate the origin of Lophora’s proprietary class of Serotonin 2A receptor agonists and the discovery of this potentially life-altering drug.